ECM
PCVX icon

Endurant Capital Management’s Vaxcyte PCVX Stock Holding History

Endurant Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-52,309
Closed -$1.25M – 68
2022
Q3 		$1.25M Buy
+52,309
New +$1.33M 0.41% 40
2020
Q3 		– Sell
-6,827
Closed -$216K – 69
2020
Q2 		$216K Buy
+6,827
New +$220K 0.01% 55

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Endurant Capital Management's PCVX Position: Q4 2022 in Review

Endurant Capital Management sold out of Vaxcyte (PCVX) in Q4 2022, closing a stake of 52,309 shares — an estimated $1.25M sold.

Endurant Capital Management first reported a position in PCVX in Q2 2020 and held it in 2 quarters. The position peaked at $1.25M in Q3 2022. 198 funds tracked by Wall St. Rank hold PCVX as of Q4 2022.

  • Endurant Capital Management reported no remaining Vaxcyte position as of Q4 2022 after selling out during the quarter.
  • Endurant Capital Management sold 52,309 Vaxcyte shares in Q4 2022, an estimated $1.25M.
  • Endurant Capital Management first reported a position in Vaxcyte in Q2 2020 and held it in 2 quarters.
  • Endurant Capital Management's Vaxcyte position peaked at $1.25M in Q3 2022.
  • 198 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2022.

Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.